Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

2(33.3%)

Phase 1

2(33.3%)

Phase 2

1(16.7%)

Phase 3

1(16.7%)

6Total

N/A(2)

Phase 1(2)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT02658565Not ApplicableActive Not Recruiting

Selective Surgical Staging for the Treatment of Endometrial Cancer Based on Intraoperative Consultation

Role: lead

NCT04608409Phase 1Completed

Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer

Role: lead

NCT04805333Phase 1Completed

Phase 1 Dose Escalation of ArtemiCoffee

Role: lead

NCT04970368Phase 3Terminated

Comparison of Nodal Staging in Endometrial Cancer

Role: lead

NCT02227654Not ApplicableCompleted

Evaluating the Performance of Morphology Index in Surgical Decision-Making for Ovarian Tumors

Role: lead

NCT01512810Phase 2Completed

Intraoperative Pathological Evaluation for Surgical Treatment & Staging for Endometrial Cancer

Role: lead

All 6 trials loaded